date:Jul 21, 2012
portunity to enlarge the geographic footprint of Axona.
Nestl Health Science president and CEO Luis Cantarell added: Axonais an innovative medical food with a well understood mode of action and offers the potential for personalized nutrition for AD patients.
Our stake in Accera is a strategic step forward in building up our brain health portfolio.
What is Axona?
Alzheimer's disease patients exhibit a decline in the ability to metabolize glucose in the brain, which can in turn lead to impaire